Navigation Links
New intranasal influenza vaccine triggers robust immunity with significantly less antigen
Date:10/28/2008

Washington, DC (October 26, 2008) A single administration of a novel, nasally delivered influenza vaccine elicited immune responses in ferrets that were more than 20 times higher than those generated by two injections of the currently approved vaccines, according to a study by NanoBio Corporation. The new vaccine used only half the standard antigen dose to produce this effect.

Results of the study are being presented today at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, D.C.

The company's nasal vaccines exert adjuvant activity without the need for pro-inflammatory materials, toxins or cytokines.

"Our nanoemulsion-based intranasal vaccine adjuvant system represents a paradigm shift in vaccinology. It can be used to safely deliver multiple antigen types directly into the lining of the nasal mucosa, which is rich in dendritic cells that present the antigen(s) to the immune system," said James R. Baker, Jr., M.D., founder and chairman of NanoBio Corp. "The nanoemulsion adjuvant uniquely interacts with these cells to trigger unparalleled mucosal and systemic immunity."

In the study, ferrets received 7.5, 15 and 45 micrograms of nanoemulsion-adjuvanted influenza vaccine (n=12 ferrets/dose). All three doses produced antibody responses substantially higher than those triggered by the standard intramuscular vaccine. The ferrets, which represent the most relevant influenza animal model for humans, were then challenged with live influenza virus, and all were protected.

"A large, unmet medical need still exists for protecting people from influenza infection," Baker said. "The robust immunity and antigen-sparing capability demonstrated in this study are especially important for addressing this unmet need, as are the demands for a vaccine that would protect people in the face of a flu pandemic."

NanoBio plans to begin a phase 1 clinical study for seasonal influenza in the first half of 2009 and is currently initiating preclinical studies in pandemic flu.


'/>"/>

Contact: Becky Levine
blevine@medthink.com
919-786-4918
MedThink Communications
Source:Eurekalert

Related medicine news :

1. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
2. Nanoemulsion-Based Intranasal Influenza Vaccine Adjuvant Triggers Robust Immunity Using Significantly Less Antigen
3. Bioniche Responds to Australian Equine Influenza Outbreak
4. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
5. NIH scientists describe ways to better assess benefits of influenza vaccine in the elderly
6. Launch of New Educational Campaign, Spread the Word - NOT the Flu!, Aims to Highlight Importance of Influenza Vaccination
7. Novartis Vaccines Launches National Gift-Giving Program to Help Protect Loved Ones by Reserving an Influenza Vaccination
8. Influenza: Insights into cell specificity of human vs. avian viruses
9. Childhood Influenza Immunization Coalition Issues New Report to Help Improve Low Childhood Influenza Immunization Rates
10. Health Department Reports States First Lab-Confirmed Influenza Case of the Season
11. Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... “Monique”: is the story of Monique, ... the creation of published author, Colleen Crispi, has owned four beauty salons and written ... involved in real estate and cooking. , “The doctor’s office was only three ...
(Date:9/19/2017)... ... 2017 , ... Only a few physicians were selected to receive the prestigious ... Clevens, MD, FACS . The founder and medical director of Clevens Face and ... at Yale, Harvard and the University of Michigan. He has served patients throughout Central ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... St. Vincent’s Infusion Services called, “PAPA Healthcare helps fill gaps, provide essential insights, ... enhanced service delivery and operations by leveraging PAPA Healthcare’s post-acute productivity and analytics ...
(Date:9/19/2017)... MD (PRWEB) , ... September 19, 2017 , ... ... Environmental Compliance and Safety for the President’s Malaria Initiative (PMI) Africa Indoor ... USAID’s Innovation to Action Award. , The Innovation to Action Award, a ...
(Date:9/19/2017)... ... 19, 2017 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... national Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... 2017   PDI , a leader in infection ... an educational session focused on the role of chlorhexidine ... at the 2017 Annual Scientific Meeting of the Association ... at the Phoenix Convention Center ... 16-19, will also feature PDI,s Prevantics® Device Swab ...
(Date:9/5/2017)... 5, 2017  Xyntek Inc. has announced another milestone in their continued growth ... to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams Street, Suite ... Xyntek's ... ...
(Date:9/1/2017)... Sept. 1, 2017 Michael Penna , ... , highlights opportunities for growth in his response to ... Marlin Equity is seeking a buyer for eMDs. Penna,s ... 22-year-old healthcare solutions Value Added Reseller and national leader ... "As the healthcare market continues to ...
Breaking Medicine Technology: